Tasly Pharmaceutical Group Co Ltd
SSE:600535

Watchlist Manager
Tasly Pharmaceutical Group Co Ltd Logo
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Watchlist
Price: 14.47 CNY -4.43% Market Closed
Market Cap: 21.6B CNY
Have any thoughts about
Tasly Pharmaceutical Group Co Ltd?
Write Note

Tasly Pharmaceutical Group Co Ltd
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tasly Pharmaceutical Group Co Ltd
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Other Equity
ÂĄ104.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Equity
ÂĄ136.9m
CAGR 3-Years
N/A
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Equity
ÂĄ2.3m
CAGR 3-Years
-78%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Equity
ÂĄ18.5m
CAGR 3-Years
N/A
CAGR 5-Years
44%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Equity
-ÂĄ36.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Equity
ÂĄ1.4m
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tasly Pharmaceutical Group Co Ltd
Glance View

Market Cap
21.6B CNY
Industry
Pharmaceuticals

Tasly Pharmaceutical Group Co., Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The company is headquartered in Tianjin, Tianjin and currently employs 9,437 full-time employees. The company went IPO on 2002-08-23. The firm's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The firm's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The firm mainly distributes its products in the domestic market.

Intrinsic Value
19.81 CNY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Tasly Pharmaceutical Group Co Ltd's Other Equity?
Other Equity
104.5m CNY

Based on the financial report for Jun 30, 2024, Tasly Pharmaceutical Group Co Ltd's Other Equity amounts to 104.5m CNY.

What is Tasly Pharmaceutical Group Co Ltd's Other Equity growth rate?
Other Equity CAGR 1Y
-6%

Over the last year, the Other Equity growth was -6%.

Back to Top